Description: This article provides the reader with some insights regarding tax planning under the new required methodology.

Description: A statement about the article peer-review process for the newsletter, and a disclaimer about interpreting any article content as tax, legal, or other advice.

Description: Read the February 2020 issue of Taxing Times, published by the Taxation Section. Newsletters provide practical information for the working actuary, articles on trends that impact sections and news about section activities.

Description: Canada has been proactive in establishing governance frameworks for reinsurance transactions. Initiatives from individuals, the Office of the Superintendent of Financial Institutions OSFI and the Canadian Institute of Actuaries CIA have addressed concerns about and scrutiny of reinsurance transactions from worldwide securities and insurance regulators, rating agencies and the media. It is important to note that actuaries have played a vital role in identifying and developing these initiatives and will continue to have a major influence in further development of governance standards and in providing education. From The Actuary Magazine June 2007

Description: S&P Global published a revised insurance capital model in November 2023. The revisions add considerable complexity to their insurance capital model and rely more on companies to fill out the detailed model inputs. In return, the new model allows for better risk differentiation and an overall better assessment of insurance company risk-adjusted capitalization. In this session we will review the new capital model in-depth, considering its implications for capital management and product development. By the end of the session, attendees should have a deeper understanding of the revised criteria of the S&P insurance capital model, including its most important risk drivers and how it relates to the AM Best 'BCAR' and the NAIC RBC capital models.

Description: IUL continues to be the strongest selling UL product. Companies have great profit/pricing expectations, but are those results being achieved? Learn about potential areas of underperformance for IUL including behavior related issues, hedging inefficiency, and mortality issues. The session will also discuss ways to monitor these risks and discuss different means to address potential issues of underperformance in hedging, pricing and in force earnings.

Description: Learn about the innovations of life & health products and distribution in the Asia market.

Description: Almost half of recent FDA approvals have been for orphan drugs. This trend is expected to continue in 2023. Orphan drugs are priced more than 30 times higher than non-orphan drugs, therefore their cost burden in aggregate has the potential to overwhelm the budgets of payers, especially that of smaller health plans. Hear how the cost impact analysis for smaller health plans require different considerations than for a larger health plan when modeling the impact of rare diseases.

Description: Reunite with members and non-members in the China actuarial community to discuss recent topics and related issues in areas such as macroeconomic sharing, IFRS 17, product strategy, cross-border communication and discussion, and more. Advance your career through learning and networking opportunities, and share your experiences in the finance and insurance industries, as well as other fields related to actuarial science.

Description: Have you wondered: - As a U.S. insurer, should I try to understand the implication of International Financial Reporting Standard 17 (IFRS 17) on global insurers? - As a pricing actuary, do I need to learn about the financial evolution brought about by IFRS 17 and Long Duration Targeted Improvements (LDTI)? - As my organization's CFO, I have invested in the arduous implementation of the new standards. How do I get the best return on my investment?If the answer to any of the above is 'Yes,' then this session is for you!